BioCardia
BioCardia is developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
BioCardia is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Its lead program is CardiAMP® autologous mononuclear cell therapy for ischemic heart failure of reduced ejection fraction (HFrEF). The company also has a pipeline including CardiALLO™ and PulmALLO™.
History
BioCardia is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Its lead program is CardiAMP® autologous mononuclear cell therapy for ischemic heart failure of reduced ejection fraction (HFrEF). The company also has a pipeline including CardiALLO™ and PulmALLO™.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/biocardia · Editorial policy · How profiles are compiled